Navigation Links
Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit
Date:9/22/2008

Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today launched BioNuesisTM, the only soluble human extracellular matrix (ECM) developed as a culturing kit for stem cell growth. The kit was launched and is being exhibited at the 2008 World Stem Cell Summit taking place in Madison, Wisconsin.

San Diego, CA (PRWEB) September 22, 2008 -- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today launched BioNuesisTM, the only soluble human extracellular matrix (ECM) developed as a culturing kit for stem cell growth. The kit was launched and is being exhibited at the 2008 World Stem Cell Summit taking place in Madison, Wisconsin.

Through its proprietary bioreactors, Histogen is uniquely capable of simulating the embryonic environment, creating products that are embryonic-like in nature without the utilization of embryonic stem cells. Products are developed by extracting the proteins and growth factors produced by these fibroblasts. In working with the unique liquid formulation, Histogen researchers identified the potential for the human soluble ECM in the field of stem cell research, as compared to currently available products.

"There is a significant need for an all-human ECM product that can support pluripotent huES cell expansion in culture, without the complications inherent with mouse tumor-derived ECM extracts that are still the best replacement for feeder-layer cells," Dr. Jeanne Loring, Director of the Center for Regenerative Medicine at Scripps Research Institute. "Histogen's technology may provide the solution and help accelerate both basic science and translational research using huES cells."

BioNuesis is the first product that provides a limitless source of the natural human ECM proteins, such as laminin, collagen type 4 and fibronectin, which are required to expand human ES cells to commercial-scale.

Because current products utilize non-human sources, and can even contain mouse viruses, stem cell therapies developed using these animal products are not likely to be approved by the FDA. The technology behind the BioNuesis research kit, soluble natural human ECM, offers a solution which will eventually facilitate translation of stem cell cures to the public.

The launch of BioNuesis marks the entrance of Histogen into the marketplace as a number of products based on Histogen's proprietary technology continue down the pipeline.

"Histogen is uniquely capable of utilizing every aspect of the liquid and solid created by the Company's proprietary technology process, and developing high-value, all-human products at a commercial scale," said Dr. Gail Naughton, CEO of Histogen. "We are excited to bring our first product to the stem cell research market, and look forward to launching products in the cosmeceutical and medical fields in the near future."

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products without the use of embryonic stem cells or animal products. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the company has developed its rich product portfolio. Histogen has two product families - ExceltrixTM, Histogen's human Extracellular Matrix (ECM) and ReGenicaTM, Histogen's proprietary liquid formula. For more information, please visit http://www.histogeninc.com.

About the World Stem Cell Summit
The World Stem Cell Summit, to be held Sept. 22-23, 2008 at Madison's Alliant Center, is a gathering of scientists, company leaders, ethicists, investors and others. The Summit will provide an opportunity for the exchange of important stem cell information among key players from throughout the globe. The event will coincide with the 10-year anniversary of UW-Madison scientist James Thomson becoming the first to successfully isolate and culture human embryonic stem cells. For more information about the Summit, visit http://www.worldstemcellsummit.com.

###

Read the full story at http://www.prweb.com/releases/BioNuesis/Histogen/prweb1355104.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. Novozymes Launches Enzyme to Reduce Acrylamide in Food
3. Enova Medical Launches Exos Corporation
4. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
5. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
6. ThirdBiotech Networking Group Launches
7. BioReliance Launches Next-Generation Genotoxicity Screening Service
8. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
9. BioReliance Corporation Launches iNet(TM) for Online Results Tracking of Biological Safety Tests
10. Kingfisher Healthcare Launches Breakthrough Product in Europe
11. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") (en.tusholdings.com) ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
Breaking Biology News(10 mins):